OncoMatch/Clinical Trials/NCT06072807
Brain [18F]-FES PET/CT in Patients With Estrogen-Receptor Positive Breast Cancer
Is NCT06072807 recruiting? Yes, currently enrolling (May 2026). This Phase 4 trial studies non-drug interventions for breast cancer.
The goal of this interventional study is to optimize the protocol of FES PET/CT in Estrogen Receptor positive Breast cancer patients with Brain metastases. Patients will undergo MRI of the brain and FDG PET/CT brain as part of standard of care for radiation treatment planning. An additional 18F-FES PET/CT brain scan will be completed before this standard of care radiation treatment. Patients will be followed prospectively with clinical and MRI assessments per standard-of-care for a total of 12 months. Study Population: Patients with ER-positive breast cancer with biopsy proven or suspected new or recurrent brain metastases (based on standard of care MRI) planned for radiation treatment of brain lesions.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Biomarker criteria
Required: ESR1 positive
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: estrogen receptor modulator
Exception: must be discontinued for at least 8 weeks
Discontinuation of ER modulators for at least 8 weeks
Cannot have received: estrogen receptor down regulator
Exception: must be discontinued for at least 28 weeks
discontinuation of ER down regulators for at least 28 weeks
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- New York-Presbyterian/Weill Cornell Medical Center · New York, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify